ID | 1011 |
Name of the vaccine | Tdvax |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Toxoid |
Nucleic acid content | DNA |
Age | 7 years and older |
Description of the vaccine | Tetanus and Diphtheria Toxoids Adsorbed (Td vaccine). |
Name of the manufacturer | MassBiologics |
Name of the manufacturing country | United States |
Year of manufacture | 2018 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive bacillus. |
Efficacy | 50% had antitoxin concentrations of 0.01 or greater after 2 doses of Tdvax in primary series. In booster doses, all achieved an antitoxin titer of 0.01 units/mL or higher. |
Vaccine formulation | Sterile vaccine |
Dosage | Primary Immunization - Three 0.5 mL doses.
Routine Booster - in children 11-12 years of age and every 10 years. |
Mechanism of action | Serum diphtheria antitoxin level of 0.01 IU/mL provides lowest level giving some degree of protection. |
Route of administration | Intramuscular |
Indications | Active immunization for the prevention of tetanus and diphtheria. |
Export | Distributed by Grifols USA |
Approval | US FDA |
Adjuvant | Aluminium adjuvant |
Repurposing | For tetanus also. |
Side effects of vaccine | Pain, tenderness, erythema, induration, pruritis, swelling and warmth, peripheral oedema, pyrexia, malaise, dizziness, headache, convulsions, myalgia, musculoskeletal stiffness or pain, arthralgia, rash, nausea and Cellulitis. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/76430/download |
Other name | NA |
Additional Links | NA
|